InterMune, Inc. has reached a definitive agreement to sell its Actimmune (interferon gamma-1b) rights to Vidara Therapeutics International Ltd. for $55 million in cash, plus two years of royalty payments. Vidara is part of an international specialty pharma group of companies with operations in Ireland and the U.S. The transaction is expected to close during 2Q12, subject to certain closing conditions.   Dan Welch, chairman, chief executive officer and president of InterMune, said, “Several...